A Study of Stem Cells and Filgrastim

Study Overview
=================
Brief Summary
-----------------
To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure.

Detailed Description
-----------------
Patients and volunteers receive seven daily subcutaneous injections of G-CSF. On days 5 and 6 of drug administration, patients have peripheral blood mononuclear cells harvested by leukapheresis. HIV-positive patients are stratified into three cohorts based on CD4 count and presence of symptoms. If no increase in number of harvested stem cells and no grade 4 bone pain toxicity occur in two of the first three patients in a cohort, then the last three patients in that cohort will receive a dose escalation. Patients are followed for 24 weeks.

Official Title
-----------------
A Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using Filgrastim

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Filgrastim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: PCP prophylaxis. Antiretroviral therapy in patients with CD4 counts <= 500 cells/mm3. Narcotic analgesics for grade 3/4 bone pain toxicity. Patients must have: HIV infection. HIV infected patients with CD4 count > 500 cells/mm3 must be asymptomatic. Patients with CD4 count 200-500 cells/mm3 may be either asymptomatic or symptomatic but must not have AIDS. Patients with CD4 count < 200 cells/mm3 may or may not have AIDS-defining conditions. No antiretroviral therapy within the past 30 days in patients with asymptomatic disease and CD4 count > 500 cells/mm3. Stable antiretroviral therapy for the past 60 days if CD4 count <= 500 cells/mm3. Suitable venous access. Prior Medication: Allowed: Prior antiretroviral therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Current malignancy. Any medication condition that interferes with study evaluation. Known hypersensitivity to E. coli-derived proteins (e.g., insulin, human growth hormones). Concurrent Medication: Excluded: Acute treatment for serious opportunistic infection. Systemic cytotoxic chemotherapy. Concurrent Treatment: Excluded: Systemic radiation therapy. Patients with the following prior conditions are excluded: Prior malignancy. Leukapheresis or lymphopheresis within the past 180 days. Significant active CNS disease or seizures within the past year. Prior Medication: Excluded: G-CSF or GM-CSF within the past 6 months. Investigational antiretrovirals within the past 30 days. Treatment for opportunistic infection within the past 14 days. Active alcohol or substance abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Filgrastim|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS-Related Complex, Granulocyte Colony-Stimulating Factor, Acquired Immunodeficiency Syndrome, Stem Cells